Cardioprotection is alive but remains enigmatic the nitric oxide–Protein kinases–Mitochondria signaling axis

Circulation

Volumn 136, Issue 24, 2017, Pages 2356-2358

  Heusch, Gerd ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cardioprotection; Editorials; Ischemia; Mitochondrium; Reperfusion; Signaling

Indexed keywords

ACETYLCYSTEINE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLOSPORINE; GUANYLATE CYCLASE; NITRIC OXIDE; NITRITE; POTASSIUM CHANNEL; PROTEIN KINASE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL;

ACUTE HEART INFARCTION; AUTOPHAGY; EDITORIAL; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; MITOCHONDRION; NONHUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CARDIAC MUSCLE CELL; REPERFUSION INJURY;

HUMANS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MITOCHONDRIA; MYOCYTES, CARDIAC; NITRIC OXIDE; PROTEIN KINASES; REPERFUSION INJURY;

EID: 85045644609     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.031978     Document Type: Editorial

References (14)

1. Rossello X, Yellon DM. Cardioprotection: the disconnect between bench and bedside. Circulation. 2016;134:574–575. doi: 10.1161/CIRCULA-TIONAHA.116.022829.
2. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J. 2017;38:774–784. doi: 10.1093/eurheartj/ehw224.
3. Lefer DJ, Marbán E. Is cardioprotection dead? Circulation. 2017;136:98–109. doi: 10.1161/CIRCULATIONAHA.116.027039.
4. Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016;111:70. doi: 10.1007/s00395-016-0588-8.
5. Heusch G, Rassaf T. Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ Res. 2016;119:676–695. doi: 10.1161/CIRCRESAHA.116.308736.
6. Heusch G. Critical issues for the translation of cardioprotection. Circ Res. 2017;120:1477–1486. doi: 10.1161/CIRCRESAHA.117.310820.
7. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015;116:674–699. doi: 10.1161/CIRCRESAHA.116.305348.
8. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation. 2008;118:1915–1919. doi: 10.1161/CIRCULATIONAHA.108.805242.
9. Cohen MV, Downey JM. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015;172:1913–1932. doi: 10.1111/bph.12903.
10. Pasupathy S, Tavella R, Grover S, Raman B, Procter NEK, Du YT, Maha-davan G, Stafford I, Heresztyn T, Holmes A, Zeitz C, Arstall M, Selva-nayagam J, Horowitz JD, Beltrame JF. Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction reduces myocardial infarct size (the NACIAM trial [N-acetylcysteine in Acute Myocardial Infarction]). Circulation. 2017;136:894–903. doi: 10.1161/CIRCULA-TIONAHA.117.027575.
11. Campo G, Pavasini R, Morciano G, Lincoff AM, Gibson CM, Kitakaze M, Lonborg J, Ahluwalia A, Ishii H, Frenneaux M, Ovize M, Galvani M, Atar D, Ibanez B, Cerisano G, Biscaglia S, Neil BJ, Asakura M, Engstrom T, Jones DA, Dawson D, Ferrari R, Pinton P, Ottani F. Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. Int J Cardiol. 2017;244:59–66. doi: 10.1016/j.ijcard.2017.06.040.
12. Frankenreiter S, Bednarcyk P, Kniess A, Bork NI, Straubinger J, Koprowski P, Wrzosek A, Mohr E, Logan A, Murphy MP, Gawaz M, Krieg T, Sze-wczyk A, Nikolaev VO, Ruth P, Lukowski R. cGMP-elevating compounds and ischemic conditioning provide cardioprotection agianst ischemia and reperfusion injury via cardiomyocyte-specific BK channels. Circulation. 2017;136:2337–2355. doi: 10.1161/CIRCULATIONAHA.117.028723.
13. Konstantinidis K, Whelan RS, Kitsis RN. Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol. 2012;32:1552–1562. doi: 10.1161/ATVBAHA.111.224915.
14. Heusch G. The Coronary Circulation as a Target of Cardioprotection. Circ Res. 2016;118:1643–1658. doi: 10.1161/CIRCRESAHA.116.308640.